Lydia Lopez-Manzanares
Overview
Explore the profile of Lydia Lopez-Manzanares including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos-Garcia D, Lopez-Manzanares L, Muro I, Lorenzo-Barreto P, Casas Pena E, Garcia-Ramos R, et al.
Brain Sci
. 2025 Jan;
14(12.
PMID: 39766443
Background And Objective: Staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (Motor; Non-motor; Cognition; Dependency) and five stages, correlated with disease severity, patients'...
2.
Santos-Garcia D, Lopez-Manzanares L, Muro I, Lorenzo-Barreto P, Casas Pena E, Garcia-Ramos R, et al.
Eur J Neurol
. 2024 Oct;
32(1):e16535.
PMID: 39466665
Background And Purpose: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion is a recently developed device-aided therapy for advanced Parkinson disease (PD) patients. The aim of this study was to report real-world evidence...
3.
Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E, Laabs B, et al.
Brain
. 2024 Aug;
147(8):2652-2667.
PMID: 39087914
Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has...
4.
Espay A, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira J, et al.
Lancet Neurol
. 2024 Mar;
23(5):465-476.
PMID: 38499015
Background: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer...
5.
Freire-Alvarez E, Vanni P, Kurca E, Lopez-Manzanares L, Kovacs N, Spanaki C, et al.
Neurol Ther
. 2024 Feb;
13(2):437-447.
PMID: 38345741
Introduction: The DYSCOVER study was a phase 3b, open-label, randomized trial (NCT02799381) that evaluated levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) in patients with Parkinson's disease (PD) and...
6.
Manez-Miro J, Vivancos-Matellano F, Alonso-Frech F, Vela-Desojo L, Lopez-Ariztegui N, Lopez-Manzanares L, et al.
Mov Disord Clin Pract
. 2022 Nov;
9(8):1085-1093.
PMID: 36339297
Background: Dopamine replacement therapy reduces most motor and nonmotor features of Parkinson's disease. However, with disease progression, adjustments of dopaminergics and the application of advanced therapies must be considered. Objectives:...
7.
Guerra-Hiraldo J, Lopez-Jimenez A, Gasca-Salas C, Maycas-Cepeda T, Gomez-Sanchez P, Lopez-Manzanares L, et al.
J Neurol
. 2022 Aug;
270(1):548-551.
PMID: 35925399
No abstract available.
8.
Pagano G, Taylor K, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al.
N Engl J Med
. 2022 Aug;
387(5):421-432.
PMID: 35921451
Background: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease....
9.
Perez-Lopez C, Hernandez-Vara J, Caballol N, Bayes A, Buongiorno M, Lopez-Ariztegui N, et al.
Front Neurol
. 2022 Jun;
13:835249.
PMID: 35651347
Background: For specialists in charge of Parkinson's disease (PD), one of the most time-consuming tasks of the consultations is the assessment of symptoms and motor fluctuations. This task is complex...
10.
Martinez-Horta S, Bejr-Kasem H, Horta-Barba A, Pascual-Sedano B, Santos-Garcia D, de Deus-Fonticoba T, et al.
BMC Neurol
. 2021 Dec;
21(1):477.
PMID: 34879838
Background: Identifying modifiable risk factors for cognitive impairment in the early stages of Parkinson's disease (PD) and estimating their impact on cognitive status may help prevent dementia (PDD) and the...